TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18619812

Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibitors
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibitors and atypical antipsychotics
Number of subjects: 33
Study: 15890493

Group type: EXPERIMENTAL
Intervention: Increased social activities or satisfaction
Number of subjects: 44

Group type: COMPARATOR
Intervention: Disruptions in social relations
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Positive changes in social relations
Number of subjects: 44
Study: 14571154

Group type: EXPERIMENTAL
Intervention: Olanzapine 15 mg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Risperidone 4 mg
Number of subjects: 44
Study: 11220983

Group type: EXPERIMENTAL
Intervention: Milk fermented by Lactobacillus casei (10(8) cfu/ml)
Number of subjects: 928

Group type: COMPARATOR
Intervention: Standard yogurt
Number of subjects: 928
Study: 8818493

Group type: EXPERIMENTAL
Intervention: High-resolution ultrasound examination
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (normal population)
Number of subjects: 43
Study: 1433774

Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Semirecumbent position
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Patients with NGT
Number of subjects: 70

Group type: COMPARATOR
Intervention: Patients without NGT
Number of subjects: 70
Study: 3893598

Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Maintenance clinic
Number of subjects: 100
Study: 29787409

Group type: EXPERIMENTAL
Intervention: Ultrasound group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Palpation group
Number of subjects: 60
Study: 29898344

Group type: EXPERIMENTAL
Intervention: Care based on Swanson's theory of caring
Number of subjects: 43

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 43
Study: 27248467

Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: WBRT
Number of subjects: 14
Study: 24233282

Group type: EXPERIMENTAL
Intervention: Baseline depression (BDI-II score > 13)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Lower executive function
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Lower memory performance
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Pretransplant depression and anxiety
Number of subjects: 201
Study: 21349594

Group type: COMPARATOR
Intervention: 5 mg rosuvastatin
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: 40 mg rosuvastatin
Number of subjects: 87
Study: 19926203

Group type: EXPERIMENTAL
Intervention: Direct Optical Access (DOA)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Verres needle (classical closed method)
Number of subjects: 194
Study: 17334952

Group type: EXPERIMENTAL
Intervention: Educational campaign regarding stroke knowledge
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Demographic factors (age, sex, education)
Number of subjects: 422
Study: 15757856

Group type: EXPERIMENTAL
Intervention: Single high dose FSH (375 IU) during the early follicular phase (group A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5 consecutive low doses FSH (75 IU/day) starting in the mid follicular phase (group B)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daily low doses FSH (75 IU/day) during the early to late follicular phase (groups C, D, E)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Natural cycle (control)
Number of subjects: 0
Study: 10683601

Group type: EXPERIMENTAL
Intervention: Androstenedione supplementation (200 mg daily for 2 days)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Androstenedione supplementation with heavy resistance exercise
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 10
Study: 9587536

Group type: EXPERIMENTAL
Intervention: Vaccination group: 3 i.m. injections of GenHevac B followed by one booster at month 9
Number of subjects: 25

Group type: COMPARATOR
Intervention: Serovaccination group: same vaccination schedule followed by one i.m. injection of anti‐HBs immunoglobulins (500 IU)
Number of subjects: 25
Study: 8314383

Group type: EXPERIMENTAL
Intervention: Aminoglutethimide (AGT) 125 mg twice daily
Number of subjects: 56

Group type: COMPARATOR
Intervention: Hydrocortisone (HC) 20 mg twice daily
Number of subjects: 56
Study: 3492816

Group type: EXPERIMENTAL
Intervention: Chronic-disease data-bank system
Number of subjects: 0
Study: 30103792

Group type: EXPERIMENTAL
Intervention: Cannulated screw locking plate (CSLP)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Multiple cancellous screws (MCS)
Number of subjects: 68
Study: 26791936

Group type: EXPERIMENTAL
Intervention: Cluster sets of 2 (CS2)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cluster sets of 4 (CS4)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Traditional sets (TS)
Number of subjects: 12
Study: 23731911

Group type: EXPERIMENTAL
Intervention: Dopamine agonists (rotigotine or cabergoline)
Number of subjects: 40

Group type: COMPARATOR
Intervention: L-dopa
Number of subjects: 40

Group type: COMPARATOR
Intervention: Off therapy
Number of subjects: 40
Study: 21424279

Group type: EXPERIMENTAL
Intervention: Progressive, moderate-intensity resistance + impact training
Number of subjects: 106
Study: 18504322

Group type: EXPERIMENTAL
Intervention: Energy intake-restricted weight loss (n=26)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Attention control (n=14)
Number of subjects: 40
Study: 16996879

Group type: EXPERIMENTAL
Intervention: LIGHT (40% of maximal oxygen consumption)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: MODERATE (60% of maximal oxygen consumption)
Number of subjects: 50

Group type: COMPARATOR
Intervention: nonexercise control
Number of subjects: 50
Study: 12599025

Group type: EXPERIMENTAL
Intervention: Surgery without drainage in pancreatic resections
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Avoiding drainages in colorectal surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Use of drainages in perforated appendicitis
Number of subjects: 0
Study: 10743984

Group type: EXPERIMENTAL
Intervention: Critical pathway (levofloxacin treatment)
Number of subjects: 1743

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 1743
Study: 9406110

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 1548352

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (10 mg/day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 15
Study: 3771813

Group type: EXPERIMENTAL
Intervention: Propranolol 640 mg/day
Number of subjects: 13
Study: 29789302

Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study: 27543797

Group type: EXPERIMENTAL
Intervention: ABT-719 800 μg/kg
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: ABT-719 1600 μg/kg
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: ABT-719 2100 μg/kg
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 24987970

Group type: EXPERIMENTAL
Intervention: Fibrin glue application
Number of subjects: 26
Study: 21737704

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1 g bolus before incision, 400 mg/h infusion during surgery)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 231

Group type: COMPARATOR
Intervention: Placebo (saline solution infusion)
Number of subjects: 231
Study: 20164695

Group type: EXPERIMENTAL
Intervention: Paclitaxel/carboplatin/etoposide (PCE)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Gemcitabine/irinotecan
Number of subjects: 198
Study: 18217908

Group type: EXPERIMENTAL
Intervention: Once-daily cyclosporine dosing (group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Once-daily cyclosporine dosing with 25% dose reduction (group C)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Twice-daily cyclosporine dosing (group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Conversion to once-daily dosing
Number of subjects: 60
Study: 19880675

Group type: EXPERIMENTAL
Intervention: SB-681323 7.5 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: SB-681323 25 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Prednisolone 30 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Prednisolone 10 mg
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 16314594

Group type: EXPERIMENTAL
Intervention: Trained physicians in communication skills
Number of subjects: 1785

Group type: COMPARATOR
Intervention: Untrained physicians
Number of subjects: 1785

Group type: EXPERIMENTAL
Intervention: Illness perceptions of 'uncertainty'
Number of subjects: 1785

Group type: EXPERIMENTAL
Intervention: Illness perceptions of 'emotional representations'
Number of subjects: 1785
Study: 11903939

Group type: EXPERIMENTAL
Intervention: Epidural morphine (0.1 mg x kg(‐1) in 0.2 ml x kg(‐1) saline)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Patient-controlled analgesia (PCA) morphine (0.1 mg x kg(‐1) i.v. immediately after intubation, with postoperative bolus doses of 0.5 mg, 1 mg, or 1.5 mg based on weight)
Number of subjects: 44

Group type: COMPARATOR
Intervention: PCA morphine
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both techniques (Epidural and PCA)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Epidural morphine
Number of subjects: 44
Study: 9783498

Group type: EXPERIMENTAL
Intervention: Bisoprolol (5 mg/d for 12 weeks, increased to 10 mg/d if DBP >= 95 mm Hg after 4 weeks)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bisoprolol (5 mg/d)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (2-week run-in period)
Number of subjects: 60
Study: 7940622

Group type: EXPERIMENTAL
Intervention: Referral message linking family planning and EPI services
Number of subjects: 0
Study: 3665118

Group type: EXPERIMENTAL
Intervention: Transsphenoidal surgery for large non‐functioning pituitary tumours
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Pre‐operative bromocriptine therapy
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Transsphenoidal surgery for non‐invasive macroprolactinomas
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Transsphenoidal surgery for meso‐prolactinomas and microprolactinomas
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Pre‐operative bromocriptine therapy for macroprolactinomas
Number of subjects: 58

Group type: COMPARATOR
Intervention: Surgery vs. radiotherapy for invasive prolactinomas and macroprolactinomas with uneven shrinkage
Number of subjects: 58

Group type: COMPARATOR
Intervention: Surgery for microprolactinomas
Number of subjects: 58
Study: 31342245

Group type: EXPERIMENTAL
Intervention: Monofilament and synthetic sutures
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: All sutures
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Non-resorbable polypropylene suture
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Non-resorbable silk suture
Number of subjects: 32
Study: 28627254

Group type: EXPERIMENTAL
Intervention: 6-month lifestyle physical activity intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 60
Study: 25947264

Group type: EXPERIMENTAL
Intervention: 15 mg/kg of oral paracetamol, 60 min before examination
Number of subjects: 114
Study: 23995795

Group type: EXPERIMENTAL
Intervention: Narrow-band ultraviolet B (NB-UVB) treatment
Number of subjects: 12
Study: 22524633

Group type: EXPERIMENTAL
Intervention: Early removal group (ERG)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Standard group (SG)
Number of subjects: 205
Study: 20402438

Group type: EXPERIMENTAL
Intervention: Implementation intention intervention
Number of subjects: 349

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 349
Study: 18533780

Group type: EXPERIMENTAL
Intervention: Piezo-ceramic device
Number of subjects: 59

Group type: COMPARATOR
Intervention: Curets
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Both groups (Piezo-ceramic device and Curets)
Number of subjects: 59
Study: 16128794

Group type: EXPERIMENTAL
Intervention: Non-zinc toothpastes
Number of subjects: 3000
Study: 12856249

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (Botox; Allergan, Ettlingen, Germany) injections into masticatory muscles
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 90
Study: 10566717

Group type: EXPERIMENTAL
Intervention: Oral midazolam (7.5 mg mixed with apple juice)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo (apple juice)
Number of subjects: 99
Study: 8735681

Group type: EXPERIMENTAL
Intervention: TROPDEX (tropisetron 5 mg i.v. + dexamethasone 20 mg i.v. on day 1, followed by oral tropisetron 5 mg daily and dexamethasone 4 mg twice daily from day 2 to 6)
Number of subjects: 36

Group type: COMPARATOR
Intervention: METDEX (metoclopramide 1 mg kg‐1 i.v. + dexamethasone 20 mg i.v. + diphenhydramine 25 mg i.v. on day 1, followed by oral metoclopramide 20 mg 6 hourly from day 2 to 6)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: TROPDEX (in second cycle)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: TROPDEX (in first cycle)
Number of subjects: 36
Study: 1768543

Group type: EXPERIMENTAL
Intervention: 4.7% MAC cyclopropane
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 8.8% MAC cyclopropane
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 5.3% MAC halothane
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 9.3% MAC halothane
Number of subjects: 6

Group type: COMPARATOR
Intervention: Halothane (both concentrations)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 6
Study: 6778574

Group type: EXPERIMENTAL
Intervention: Salbutamol (10 to 40 microgram/min)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dopamine (200 and 400 micrograms/min)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dopamine (800 micrograms/min)
Number of subjects: 12
Study: 29741443

Group type: EXPERIMENTAL
Intervention: Individualised training group (ITG, n = 9)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (CG, n = 8)
Number of subjects: 17
Study: 26563095

Group type: EXPERIMENTAL
Intervention: Brief intervention (BI)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Business as usual (BAU)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Population controls (non-intervention)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: MOH patients
Number of subjects: 60
Study: 24275013

Group type: EXPERIMENTAL
Intervention: Quetiapine fumarate extended release (QXR) 300 mg/day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Escitalopram (ESC) 10 mg/day
Number of subjects: 60
Study: 22544892

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Educational control programme
Number of subjects: 83
Study: 19028834

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 130
Study: 17940752

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5-HTTLPR genotype (LL homozygosity)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control procedures (not specified)
Number of subjects: 0
Study: 15562384

Group type: EXPERIMENTAL
Intervention: Gliclazide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 0
Study: 14976046

Group type: EXPERIMENTAL
Intervention: Prolonged rituximab administration (375 mg/m(2) every 2 months for 4 times)
Number of subjects: 202

Group type: COMPARATOR
Intervention: No further treatment after initial response or stable disease
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Prolonged rituximab administration
Number of subjects: 202

Group type: COMPARATOR
Intervention: No further treatment in chemotherapy-naive patients
Number of subjects: 202

Group type: COMPARATOR
Intervention: No further treatment in patients responding to induction treatment
Number of subjects: 202
Study: 10729688

Group type: EXPERIMENTAL
Intervention: Partially randomized patient preference (PRPP) design
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional trial methods
Number of subjects: 0
Study: 9481966

Group type: COMPARATOR
Intervention: 2% lidocaine with 1/80,000 epinephrine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1/80,000 epinephrine + 0.5% bupivacaine
Number of subjects: 0
Study: 1439632

Group type: EXPERIMENTAL
Intervention: Penicillamine
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Cyclofenil
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control (neither treatment)
Number of subjects: 29
Study: 3895024

Group type: EXPERIMENTAL
Intervention: Methicillin (200 mg/kg divided into six i.v. doses during 24 hours starting at the induction of anesthesia)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control group (no antibiotics)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Overall infection rate across both groups
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Treated group
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 152
Study: 31776740

Group type: EXPERIMENTAL
Intervention: Low-dose CT-guided lung biopsy
Number of subjects: 271

Group type: COMPARATOR
Intervention: Standard-dose CT-guided lung biopsy
Number of subjects: 271
Study: 29149455

Group type: EXPERIMENTAL
Intervention: CMR-video (video information + standard text-information)
Number of subjects: 148

Group type: COMPARATOR
Intervention: CMR-standard (standard text-information alone)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Myocardial perfusion scintigraphy
Number of subjects: 148
Study: 27091236

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 200 or 300 U administered as needed for symptom control
Number of subjects: 227
Study: 24444783

Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 22441975

Group type: EXPERIMENTAL
Intervention: Oversewing (group A)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Buttressed transection with polyglycolide acid and trimethylene carbonate (group B)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Staple-line roofing with gelatin fibrin matrix (group C)
Number of subjects: 120
Study: 20100374

Group type: EXPERIMENTAL
Intervention: Probiotic yoghurt (300 g daily for 6 weeks)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Conventional yoghurt (300 g daily for 6 weeks)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no yoghurt)
Number of subjects: 90
Study: 19074086

Group type: EXPERIMENTAL
Intervention: Thrombopoietin receptor agonists (TPO receptor agonists)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recombinant TPO
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel compounds designed to stimulate the TPO receptor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adverse effects of TPO receptor agonists
Number of subjects: 0
Study: 15905767

Group type: EXPERIMENTAL
Intervention: Balloon Kyphoplasty
Number of subjects: 51

Group type: COMPARATOR
Intervention: Vertebroplasty
Number of subjects: 51
Study: 12571854

Group type: EXPERIMENTAL
Intervention: LJP 394
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study: 9558537

Group type: EXPERIMENTAL
Intervention: Rigid fixation with bicortical position screws
Number of subjects: 127

Group type: COMPARATOR
Intervention: Wire fixation with inferior border wires
Number of subjects: 127
Study: 7700724

Group type: EXPERIMENTAL
Intervention: Vaginal delivery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Elective cesarean section
Number of subjects: 0
Study: 2791561

Group type: EXPERIMENTAL
Intervention: Routine iron supplementation
Number of subjects: 2960

Group type: COMPARATOR
Intervention: Selective iron supplementation
Number of subjects: 2960
Study: 889511

Group type: EXPERIMENTAL
Intervention: 0.125% clonidine hydrochloride solution
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 0.25% clonidine hydrochloride solution
Number of subjects: 21

Group type: COMPARATOR
Intervention: 2% pilocarpine hydrochloride solution
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Clonidine (both concentrations)
Number of subjects: 21
Study: 29289382

Group type: EXPERIMENTAL
Intervention: Edmonston-Zagreb (EZ) strain
Number of subjects: 200

Group type: COMPARATOR
Intervention: AIK-C strain
Number of subjects: 200
Study: 26099369

Group type: EXPERIMENTAL
Intervention: Low-fat milk (LFM)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Apple juice (AJ)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Water (W)
Number of subjects: 34
Study: 25167875

Group type: EXPERIMENTAL
Intervention: 2 separate injections (0.2 + 0.2 mL/kg) of contrast medium (gadoteridol) in Group A
Number of subjects: 40

Group type: COMPARATOR
Intervention: Single injection of 0.4 mL/kg of contrast medium (gadoteridol) in Group B
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups underwent delayed studies
Number of subjects: 40
Study: 22424466

Group type: EXPERIMENTAL
Intervention: Warmed breasts (breast compress warmed in a microwave oven for 1 minute at 180 W applied for 20 minutes)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Nonwarmed breasts
Number of subjects: 39
Study: 20398359

Group type: EXPERIMENTAL
Intervention: Follicular phase
Number of subjects: 38

Group type: COMPARATOR
Intervention: Luteal phase
Number of subjects: 38
Study: 18329961

Group type: EXPERIMENTAL
Intervention: iPods (four types) placed 2 inches anterior to the pacemaker for up to 10 seconds
Number of subjects: 100
Study: 16492643

Group type: EXPERIMENTAL
Intervention: Child receiving chemotherapy for cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Child with cancer in remission
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physically healthy child
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exposure to information about cancer
Number of subjects: 0
Study: 12094850

Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg once daily (group 15qd)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg on alternate days (group 30qod)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Both regimens (15 mg daily and 30 mg alternate days)
Number of subjects: 137